)
Alkermes (ALKS) investor relations material
Alkermes Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline progress and upcoming catalysts
Positive ALKS 2680 NT2 data advanced the program to Phase III; positive LUMRYZ idiopathic hypersomnia results support registration progress; positive ADHD data from orexin agonist ALKS 7290 led to clinical entry.
Roughly six trial readouts were expected over the 12 months through the end of the following year, including the idiopathic hypersomnia study at year-end, three Phase III programs around midyear, ADHD Phase II dose-ranging in early fall and ALKS 4510 fatigue after that.
Orexin agonism beyond hypersomnolence
Development beyond hypersomnolence is guided by neurotransmitter-release and pharmacology research; ADHD and MDD were identified as neuroscience areas with translational potential and a focus on probability of success and return on investment.
In MDD research, orexin agonism showed synergistic serotonin release in the prefrontal cortex and other brain areas when combined with SSRIs or SNRIs; the approach is intended to address depression biology rather than sleep symptoms alone.
NT1 and NT2 studies showed dose-responsive cognitive improvement, moving patients from moderate or severe cognitive deficits to normal; further clinical work is needed to establish a separate cognitive claim.
Maintenance data showed continued improvement with prolonged use and benefit after dose optimization; dose and duration effects will be important design considerations in ADHD and MDD studies.
Idiopathic hypersomnia and dosing
IH patients were characterized as heterogeneous and similar to NT2 patients, with intact orexin tone and expected similar effect size; long sleepers also experience excessive daytime sleepiness, while the Phase III study will quantify efficacy.
A placebo-adjusted 2–3-point ESS change was described as clinically meaningful; unmet need is substantial, and oxybates are not suitable for every patient.
NT2 maintenance data showed a spectrum of response, with patients at different dose levels normalizing over time; a subset had lower afternoon MWT performance, prompting split dosing across programs.
The upcoming clinical study will provide the first split-dose performance results in a maintenance setting.
- Six pipeline programs may report in the next 12 months as orexin studies advance across indications.ALKS
Stifel 2026 Healthcare Conference 2026 - Revenue grew as acquisition costs weighed on earnings and orexin programs advanced.ALKS
Q3 2026 - Q2 2026 revenue up 27% to $496M, with LUMRYZ growth offset by higher costs and debt.ALKS
Q2 2026 - Orexin pipeline drives growth, with strong commercial execution and expanding clinical opportunities.ALKS
Jefferies London Healthcare Conference 2024 - Phase II results for alixorexton in NT1 showed strong efficacy and safety, with Phase III plans underway.ALKS
AGM 2025 - Orexin agonist pipeline shows strong efficacy and safety, positioning for broad market impact.ALKS
Goldman Sachs 46th Annual Global Healthcare Conference - Alixorexton showed significant efficacy and safety in NT2, supporting phase III advancement.ALKS
Study Update - ALKS-2680 improves wakefulness and sleep latency with strong safety and CNS expansion plans.ALKS
Status Update - Proprietary product sales rose 16% year-over-year, driving robust Q2 profitability despite lower royalties.ALKS
Q2 2024
)
)
)
)
)
)
)
)